Imugene (ASX:IMU) opened its first Australian site for a phase 1b trial investigating the use of cell therapy azercabtagene zapreleucel as a potential treatment for patients with relapsed or diffused large-B lymphoma, according to a Friday filing with the Australian bourse.
The US portion of the trial showed three patients having a complete response using the therapy, the filing said.
Patient recruitment at the Australian site is slated for November, the filing added.
The company's shares closed up more than 2% Friday.
Price (AUD): $0.05, Change: $+0.001, Percent Change: +2.22%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.